SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001654954-18-002424
Filing Date
2018-03-12
Accepted
2018-03-12 17:15:50
Documents
13
Period of Report
2018-04-27
Effectiveness Date
2018-03-12

Document Format Files

Seq Description Document Type Size
1 PROXY STATEMENT cbmg_def14a.htm DEF 14A 1134713
2 IMAGE cbmg_def14a000.jpg GRAPHIC 4371
3 IMAGE cbmg_def14a001.jpg GRAPHIC 4406
4 IMAGE cbmg_def14a002.jpg GRAPHIC 12487
5 IMAGE cbmg_def14a003.jpg GRAPHIC 14921
6 IMAGE img002.jpg GRAPHIC 39524
7 IMAGE img003.jpg GRAPHIC 26857
8 IMAGE img004.jpg GRAPHIC 47095
9 IMAGE proxy.jpg GRAPHIC 5279
10 IMAGE proxy000.jpg GRAPHIC 8253
11 IMAGE proxy001.jpg GRAPHIC 8113
12 IMAGE proxy002.jpg GRAPHIC 8542
13 IMAGE proxy003.jpg GRAPHIC 8848
  Complete submission text file 0001654954-18-002424.txt   1375790
Mailing Address 19925 STEVENS CREEK BLVD., SUITE 100 CUPERTINO CA 95014
Business Address 19925 STEVENS CREEK BLVD., SUITE 100 CUPERTINO CA 95014 (408) 973-7884
Cellular Biomedicine Group, Inc. (Filer) CIK: 0001378624 (see all company filings)

IRS No.: 861032927 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36498 | Film No.: 18684357
SIC: 2836 Biological Products, (No Diagnostic Substances)